Event Participants
Executives
4 Krishnamurthy Ganesan (Managing Director), Prashant Krishnamurthy (Executive Director & CFO), Amarendra Mohapatra (VP Finance & Accounts), Kush Mishra (Company Secretary)
Analysts
4 Indranil Basu (SN Global), Janhavi Patil (Orim Connect), Tripti Shukla (Kedia Securities)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue (FY26) | ₹328 crores | Grew from ₹264 crores in FY25; management expects ₹440-450 crores in FY27 |
| EBITDA (FY26) | ₹34.26 crores | Implies ~10.4% margin; manufacturing segment EBITDA margins at 12-13% vs trading at 5-7% |
| PAT (FY26) | ₹16.52 crores | Reflects continued profitability across FY26 |
| Revenue Mix - Technical/Active Ingredient Sales | ~55% of revenue | Trading of AI to large companies; includes technical sales |
| Revenue Mix - Manufacturing | ~40% of revenue | Includes B2B formulations, B2C (6-7% of manufacturing) and exports (8-9% of manufacturing) |
| Revenue Mix - Bio-fermented Products | ~90% of revenue | Emamectin benzoate is dominant (80-85% of manufacturing revenue) |
| IPO Proceeds Utilized (as of Mar 31, 2026) | ₹21.17 crores | 47% of net IPO proceeds utilized; monitoring agency confirmed no deviation |
| Export Revenue Split | 8-9% of manufacturing revenue | Export revenue dropped >50% YoY in FY26 due to geopolitical tensions |
| Inventory (FY26) | ₹241 crores | Built up ahead of season; imports from China require 25-35 days lead time |
| Production Capacity (Solid) | ~1,000 tons/annum | Post-expansion to reach ~2,500 tons/annum |
| Production Capacity (Liquid) | 130 lakh liters/annum | Sufficient current capacity; adding filling/packing machines |
Geographic & Segment Commentary
Domestic Business: Remains the primary revenue contributor with a dealer network of 300+ dealers across India. Strong presence in Punjab, Andhra Pradesh, Telangana and Haryana; expanding brand formulations to southern India. Q1 FY27 monsoon was weak, but rains have picked up, supporting Q2/Q3 demand expectations.
Exports: Export revenue declined >50% in FY26 due to geopolitical tensions affecting Middle East shipments. Management targeting export revenue at 10-12% of total revenue in FY27, growing to 15-20% over time. Pending registrations expected to drive recovery - ~100 registrations pending from a Southeast Asian country, 15 in UAE, plus registrations in Taiwan and Turkey.
Manufacturing vs Trading: Post-2021, manufacturing capacity commissioned at the Dahej facility. Current mix is ~55% technical/AI trading and ~40% manufacturing; management targeting 70% manufacturing revenue share in coming years as expansion completes.
Company-Specific & Strategic Commentary
R&D and Registrations: Company maintains dedicated R&D for formulations and is constructing R&D for technical synthesis. Pipeline of 10-12 products under registration; expecting 2-3 new registrations every year from FY26 onward. New molecule registration under Section 9(3) in process, expected to take 4-5 years.
Key Product Launches: Spinosad registration received (bio-fermented insecticide); awaiting registration certificate from Ministry of Agriculture. Product is low-volume, high-value, used across cash crops and organic farms - only two competitors (Corteva and one Chinese company). Spirotetramat registration also awaited (pollinator-safe). Existing star products include Emamectin Benzoate, Glufosinate, and Bispyribac Sodium.
Technical Plant Construction: IPO-funded technical plant under construction with civil work started; expected completion by Q4 FY27, commercialization 1-1.5 months later. Facility will enable AI manufacturing, targeting off-patent molecules going off-patent by 2027 for both domestic and export markets.
UAE Subsidiary: Mahamaya Lifesciences FZCo established in Dubai to serve as export base for Middle East and African markets. Business currently stalled due to geopolitical issues preventing container berthing at Jebel Ali; entity can also enable direct China-to-UAE trading using registrations.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue (FY27) | ₹440-450 crores | High double-digit growth; Q1 FY27 already grew high double-digit with strong order book |
| Export Revenue (FY27E) | 10-12% of total revenue | Recovery driven by new registrations in Southeast Asia; geopolitical normalization required |
| Export Revenue (Medium-term) | 15-20% of total revenue | Target as pending registrations (~100 from one SEA country) come online over 12-24 months |
| Technical Plant | Operational by Q4 FY27 | Construction completion targeted Q4; commercialization 1-1.5 months after |
| Production Capacity | ~2,500 tons/annum solid formulations post-expansion | Supports margin expansion as manufacturing share targets 70% of revenue |
| Revenue Mix Target | Manufacturing at 70% of total revenue | Shift from trading toward higher-margin manufacturing over coming years |
Risks & Constraints
| Risk | Context |
|---|---|
| Geopolitical Disruptions | Export business declined >50% in FY26 due to Middle East tensions preventing shipments to Jebel Ali; recovery dependent on situation normalization. UAE subsidiary (15 registrations) remains non-operational pending resolution. |
| China Import Dependence | 95% of intermediates for AI manufacturing sourced from China; ~30-35 day lead times require large seasonal inventory builds (₹241 crore in FY26). Anti-dumping duties however have minimal revenue impact (product-specific, <0.1% of revenue exposure). |
| Working Capital Cycle | Debtor days increased as manufacturing share grew; agrochemical industry standard of 90-180 day payment terms for B2B customers. Operating cash flow was negative in FY26 due to inventory and receivables buildup; management states Q1 FY27 is cash positive and expects FY27 to remain positive. |
| Registration Timelines | Product registrations take 5-7 years in India (Section 9(3)/CIB), 1.5-2.5 years in Taiwan/Vietnam; delays could push export growth and new product revenue contribution. |
Q&A Highlights
Revenue Mix and Margin Profile
- Question: What is the split between technical/AI sales and manufacturing revenue? What are the margin profiles? (Analyst)
- Answer: Technical/AI trading is ~55% of total revenue; manufacturing ~40% including B2C (6-7% of manufacturing) and exports (8-9%). EBITDA margins: trading at 5-7%, manufacturing at 12-13%. Target is to increase manufacturing to 70% of total revenue over coming years. (Amarendra Mohapatra, Prashant Krishnamurthy)
Competitive Moat and Customer Relationships
- Question: Given all products are off-patent generics, how does the company compete? (Analyst)
- Answer: Registration is the primary barrier - company spends crores and waits 6-7 years to register products under Section 9(3). CIB guidelines change frequently, making new registrations harder. Company has first-mover advantage on registered molecules. All top 20-25 Indian agrochemical companies are customers due to quality reputation and R&D capabilities. (Prashant Krishnamurthy)
Export Decline and Recovery Path
- Question: Why did export sales drop more than 50% in FY26 despite optimism? (Indranil Basu)
- Answer: Geopolitical tensions caused delays - containers not berthing at Jebel Ali despite orders in hand. Registrations are being obtained (~100 pending from one SEA country). Target to restore and exceed previous export levels in FY27, with exports at 10-12% of total revenue. (Krishnamurthy Ganesan, Prashant Krishnamurthy)
Technical Plant Progress
- Question: Only ₹0.76 crore of ₹29 crore allocated has been spent on the technical plant; what's causing delays? (Analyst)
- Answer: No delay - IPO proceeds only received in November (mid-FY26); initial funds went to formulation expansion. Civil work has started and should complete in 1.5 months. Technical plant construction targeted for Q4 FY27 completion, with commercialization 1-1.5 months later. (Prashant Krishnamurthy)
Intangible Assets and Registration Capitalization
- Question: Intangible assets under development increased from ₹5 crores to ₹14 crores in FY26 - what is driving this? (Analyst)
- Answer: The increase pertains to product registration costs and market-related costs for various geographies. Revenue contribution timing depends on regulatory approvals and market conditions. (Amarendra Mohapatra)
Working Capital and Cash Flow
- Question: Operating cash flow was negative in FY26 - is this structural? (Analyst)
- Answer: Negative cash flow was driven by inventory build-up (imports from China need 30-35 days lead) and increased debtor days as manufacturing share grew (customers pay 90-180 days). Q1 FY27 is cash positive. Discussion underway with banks for forex hedging; export hedging not yet implemented. Expect positive cash flow by FY27. (Prashant Krishnamurthy, Amarendra Mohapatra)
UAE Subsidiary Strategy
- Question: What is the purpose of the Dubai subsidiary and what can it achieve? (Analyst)
- Answer: Dubai entity was established for Middle East and Africa exports with 15 UAE registrations pending. It provides credibility with large Middle East/African buyers and enables direct China-to-UAE trading using registrations (bypassing India re-export) - similar to how UPL operates. Business stalled due to geopolitical issues preventing Jebel Ali shipments. (Prashant Krishnamurthy)
Product Pipeline and Growth
- Question: What is the registration pipeline and which products are moving to commercialization? (Analyst)
- Answer: Spinosad registration received (pending certificate from Ministry); two more molecules completed and submitted to CIB for approval in upcoming Registration Committee meeting. Expect 2-3 new registrations annually. One new molecule (Section 9(3)) in process - never before introduced in India, will take 4-5 years. Pipeline of 10-12 products under registration. (Prashant Krishnamurthy)
Atul JV and Strategic Tie-ups
- Question: What is the status of the JV with Atul Limited? (Analyst)
- Answer: Final agreement received and agreed upon; awaiting signature within next few weeks as the concerned person at Atul was not in town. Also in discussions with multiple companies (beyond Sumitomo) for product tie-ups; announcements expected in coming quarters. (Prashant Krishnamurthy)
Key Takeaway
Mahamaya Lifesciences closed FY26 with revenue of ₹328 crores, EBITDA of ₹34.26 crores, and PAT of ₹16.52 crores, and management has guided to ₹440-450 crores for FY27 (high double-digit growth). The growth strategy centers on shifting the revenue mix from 55% technical/AI trading toward 70% manufacturing, expanding bio-fermented product penetration (Emamectin Benzoate drives 80-85% of manufacturing revenue), and securing new product registrations - Spinosad is the marquee launch awaiting final certificate, with 10-12 products in the pipeline. Export recovery is a key swing factor: FY26 exports declined >50% due to Middle East geopolitical disruptions, but management expects 10-12% export contribution in FY27 as registrations come online in Southeast Asia, Taiwan, and UAE. The IPO-funded technical plant (₹29 crore allocated) is slated for Q4 FY27 completion, enabling domestic AI manufacturing and positioning the company for off-patent molecule opportunities post-2027. Watch items include working capital dynamics (inventory of ₹241 crores and extended debtor days pushed FY26 operating cash flow negative), China import dependence for 95% of intermediates, and the pace of new registrations translating to incremental revenue. Management remains confident on execution, citing a differentiated registration-led moat and relationship-driven customer base covering all top 25 Indian agrochemical firms.